Onyx Pharmaceuticals Inc., of Emeryville, Calif., is expanding its Phase III European FOCUS trial, which is evaluating the efficacy and tolerability of carfilzomib, a next-generation proteasome inhibitor, in patients with relapsed and refractory myeloma. Based on overall survival data from the Phase IIb 003-A1 study, the company is changing the primary endpoint of the FOCUS trial from progression-free survival to overall survival.